The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

RA Cap­i­tal dom­i­nat­ed the crossover game in 2021, run­ning the ta­ble as a host of biotechs an­gled for a quick leap on­to the pub­lic mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.